Retacrit®

Biosimilar medicine authorized by the AEMPS

Retacrit®

ACTIVE PRINCIPLE:
Epoetin Zeta

DATE:
27/02/2008

MORE INFO

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

PRIVACY POLICY

SUBSCRIBE